2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Mun-Teng Wong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Immunwork, Inc., C520, No. 99, Lane 130, Academia Road, Section 1, Nangang, Taipei 115021, Taiwan. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Non-alcoholic Fatty Liver Disease, Obesity, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Conjugating two fatty acids (2FAs) to peptide drugs can improve pharmacokinetics and therapeutic effects. However, optimizing FA spacing, chain combination, and attachment site to simultaneously enhance albumin binding and drug efficacy remains challenging. We introduce a multiarm linker technology enabling precise control of 2FA spacing, composition, and attachment. By applying this technology to a modified glucagon-like peptide-1 (GLP-1) and screening various 2FA-GLP-1 conjugates differing in linkage, linker, and FA properties for improved albumin affinity, pharmacokinetics, and pharmacodynamics, TE-8105 emerged as a promising candidate. TE-8105 outperformed semaglutide, showing improved long-term glycemic control, weight loss, and liver health in diabetic mice, and dose-dependent weight loss and favorable body composition changes in obese mice. A distinct advantage of TE-8105 over semaglutide is its low-dose reduction of liver steatosis and improvement of liver health in nonalcoholic steatohepatitis mice. The multiarm linker technology provides a versatile platform for developing improved 2FA-peptide therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immunwork, Inc., C520, No. 99, Lane 130, Academia Road, Section 1, Nangang, Taipei 115021, Taiwan.
- T-E Meds, Inc., C423, No. 99, Lane 130, Academia Road, Section 1, Nangang, Taipei 115021, Taiwan.
ORCID-Profile: Mun-Teng Wong, Jon D Wright, Carmay Lim, Tse Wen Chang
Zitieren
APA
Wong, M. T., Lin, P. H., Lin, W. C., Peng, C. J., Wright, J. D., Lee, H. J., Chu, H. M., Lim, C., & Chang, T. W. (2025). 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02153
Vancouver
Wong MT, Lin PH, Lin WC, Peng CJ, Wright JD, Lee HJ, et al. 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02153
BibTeX
@article{Wong2025,
author = {Wong, Mun-Teng and Lin, Pei-Hsuan and Lin, Wei-Chen and Peng, Chi-Jiun and Wright, Jon D and Lee, Hui-Ju and Chu, Hsing-Mao and Lim, Carmay and Chang, Tse Wen},
title = {2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02153}
}
EUVIMED